Sudeep Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The domestic equity indices traded with substantial gains in the early trade, mirroring positive cues from Asian markets. Investors are keeping a close watch on rupee movement, FII activity, IPO activity and other global developments. The Nifty traded above the 26,000 level.

All sectoral indices traded in the green with metal, IT and media stocks leading the rally.

At 09:25 IST, the barometer index, the S&P BSE Sensex jumped 446.04 points or 0.52% to 85,370.26. The Nifty 50 index advanced 149.80 points or 0.58% to 26,117.35.

In the broader market, the S&P BSE Mid-Cap index rose 0.61% and the S&P BSE Small-Cap index jumped 0.62%.

The market breadth was strong. On the BSE, 2,344 shares rose and 751 shares fell. A total of 226 shares were unchanged.

Foreign portfolio investors (FPIs) bought shares worth Rs 1,830.89 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 5,722.89 crore in the Indian equity market on 18 December 2025, provisional data showed.

Stocks in Spotlight:

Sudeep Pharma declined 4.52% after the company?s consolidated net profit declined 6.16% to Rs 45.74 crore despite of 9.32% increase in revenue from operations to Rs 162.66 crore in Q2 FY26 over Q2 FY25.

Emmvee Photovoltaic Power rose 0.62%. The company said its wholly owned subsidiary, Emmvee Energy (EEPL), has commenced operations of a 2.5 GW solar module line at its factory in Sulibele, Hoskote Taluk, Bengaluru, Karnataka (Unit VI).

RITES advanced 1.70% after the company has signed a memorandum of understanding with the Government of Botswana to support the development and modernisation of the country?s transport infrastructure.

Numbers to Track:

The yield on India's 10-year benchmark federal paper rose 0.55% to 6.606 compared with previous session close of 6.570.

In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 89.4900 compared with its close of 89.6700 during the previous trading session.

MCX Gold futures for 5 February 2026 settlement advanced 0.82% to Rs 135,329.

The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.02% to 98.62.

The United States 10-year bond yield declined 0.29% to 4.169.

In the commodities market, Brent crude for February 2025 settlement jumped 46 cents or 0.76% to $60.93 a barrel.

Global Markets:

Asian market advanced on Monday as investors parsed China?s central bank?s decision to keep its loan prime rates steady.

The People?s Bank of China kept its 1-year and 5-year loan prime rates unchanged at 3% and 3.5% respectively, holding them for a seventh straight meeting, in line with a Reuters survey. The one-year rate influences most new and outstanding loans, while the five-year benchmark affects mortgages.

Last Friday in the U.S., stocks rose for a second winning day, boosted by Oracle, as the artificial intelligence trade regained its footing after experiencing volatility.

Oracle shares were up 6.6% after TikTok agreed to sell its U.S. operations to a new joint venture that includes the software giant and private equity investor Silver Lake.

The Nasdaq Composite rose 1.31%, closing at 23,307.62. The S&P 500 added 0.88% to close at 6,834.50. The Dow Jones Industrial Average advanced 183.04 points, or 0.38%, and settled at 48,134.89.

Powered by Capital Market - Live News

Sudeep Pharma will hold a meeting of the Board of Directors of the Company on 19 December 2025.

Powered by Capital Market - Live News

The stock was listed at Rs 733.95, exhibiting a premium of 23.77% to the issue price.

So far, the stock has hit a high of 777 and a low of 726. On the BSE, over 20.87 lakh shares of the company were traded in the counter so far.

Sudeep Pharma was subscribed 93.72 times. The issue opened for bidding on 21 November 2025 and it closed on 25 November 2025. The price band of the IPO is fixed between Rs 563 and 593 per share.

The IPO comprised a fresh issue of equity shares worth up to Rs 95 crore and an offer for sale of 1,34,90,726 equity shares aggregating up to Rs 800 crore by existing shareholders Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani, and Avani Sujit Bhayani.

The objectives for the fresh issue include Rs 75.8 crore for capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I, and the remaining amount for general corporate purposes.

The promoters are Sujit Jaysukh Bhayani, Shanil Sujit Bhayani, Avani Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources, and the Bhayani Family Trust. The promoters and promoter group hold an aggregate of 9,95,03,523 equity shares, aggregating to 89.36% of the pre-offer issued and paid-up equity share capital. Their post IPO shareholding is expected to be around 76.15%.

Sudeep Pharma is a manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries.

The business is primarily structured into two verticals. (1) The Pharmaceutical, Food, and Nutrition vertical focuses on refined, mineral-based single ingredients essential to these industries, offering key mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, and copper that support a wide range of health-focused applications. (2) The Specialty Ingredients vertical is operated through the subsidiary SNPL. It focuses on developing technology-driven, application-specific mineral and micronutrient systems. These include micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated blends. These products cater to functional foods, dietary supplements, infant and clinical nutrition, FMCG, and convenience food formulations.

In Q1 FY26, the pharmaceutical, food, and nutrition segment contributed 66.43% to revenue, and the specialty ingredients segment 33.57%. In Q1 FY2026, India contributed 41.32% to total sales, while exports accounted for 58.68%.

Ahead of the IPO, on 20 November 2025, the company raised Rs 268.49 crore from anchor investors by allotting 45.27 lakh shares at Rs 593 each to 25 anchor investors.

For the quarter ended 30 June 2025, the firm recorded a consolidated net profit of Rs 30.81 crore and sales of Rs 124.92 crore.

Powered by Capital Market - Live News

The equity shares of Sudeep Pharma (Scrip Code: 544619) are listed effective 28 November 2025 and admitted to dealings on the Exchange in the list of ''B'' Group Securities. At 09:31 IST, the pre-open indicative price of the stock was at a premium of 13.83% to the offer price of Rs 593.

Powered by Capital Market - Live News